Genmab A/S 2018 SR
The report highlights Genmab's commitment to improving patient lives through innovative antibody products while focusing on four key CSR areas: employee well-being, ethics in clinical studies, environmental impact, and business ethics. In 2018, the company maintained a diverse workforce with 55% of management positions held by women and 33% female representation on the Board of Directors. A significant milestone was the completion of a new R&D facility in Utrecht, which achieved BREEAM Excellent certification. Genmab also implemented new GDPR compliance measures and continued its focus on ethical animal research and vendor management.
Company: Genmab A/S
Sector: Professional & technical services
Country: Denmark
Year: 2018
Type: SR
Pages: 12
Back to company
Genmab A/S
Corporate Social Responsibility Report
The report highlights Genmab's commitment to improving patient lives through innovative antibody products while focusing on four key CSR areas: employee well-being, ethics in clinical studies, environmental impact, and business ethics. In 2018, the company maintained a diverse workforce with 55% of management positions held by women and 33% female representation on the Board of Directors. A significant milestone was the completion of a new R&D facility in Utrecht, which achieved BREEAM Excellent certification. Genmab also implemented new GDPR compliance measures and continued its focus on ethical animal research and vendor management.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Jan 1, 2018 - Dec 31, 2018
Fiscal Year
2018
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management